Advancing New Hope for KCNT1-Related Epilepsy
Welcome
This site is for families and caregivers exploring a new clinical trial for ABS-1230, an investigational treatment for KCNT1-related epilepsy – a rare and severe genetic epilepsy that begins in early life.
ABS-1230 is an investigational medicine that is designed to target the KCNT1 ion channel overactivity in the brain, with the goal of reducing seizures and improving quality of life, regardless of a person’s specific KCNT1 mutation.
This Phase 1b/2 clinical trial is now enrolling in the U.S. Explore this site to learn more, view key eligibility, and see if this trial may be right for your family.
Stay informed:
Sign up for email updates
If you would like to receive updates about our progress, upcoming studies, or resources for families, you can sign up for email updates.